475 related articles for article (PubMed ID: 34571905)
1. The Interplay between Glioblastoma and Its Microenvironment.
Dapash M; Hou D; Castro B; Lee-Chang C; Lesniak MS
Cells; 2021 Aug; 10(9):. PubMed ID: 34571905
[TBL] [Abstract][Full Text] [Related]
2. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
Front Immunol; 2020; 11():582106. PubMed ID: 33178210
[TBL] [Abstract][Full Text] [Related]
3. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
Lin H; Liu C; Hu A; Zhang D; Yang H; Mao Y
J Hematol Oncol; 2024 May; 17(1):31. PubMed ID: 38720342
[TBL] [Abstract][Full Text] [Related]
4. Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study.
Ali S; Borin TF; Piranlioglu R; Ara R; Lebedyeva I; Angara K; Achyut BR; Arbab AS; Rashid MH
PLoS One; 2021; 16(2):e0246646. PubMed ID: 33544755
[TBL] [Abstract][Full Text] [Related]
5. Macrophages and microglia: the cerberus of glioblastoma.
Buonfiglioli A; Hambardzumyan D
Acta Neuropathol Commun; 2021 Mar; 9(1):54. PubMed ID: 33766119
[TBL] [Abstract][Full Text] [Related]
6. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.
DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U
Front Immunol; 2020; 11():1402. PubMed ID: 32765498
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics.
Ye Z; Ai X; Zhao L; Fei F; Wang P; Zhou S
Oncogene; 2021 Oct; 40(42):6059-6070. PubMed ID: 34556813
[TBL] [Abstract][Full Text] [Related]
8. Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma.
Close HJ; Stead LF; Nsengimana J; Reilly KA; Droop A; Wurdak H; Mathew RK; Corns R; Newton-Bishop J; Melcher AA; Short SC; Cook GP; Wilson EB
Clin Exp Immunol; 2020 Apr; 200(1):33-44. PubMed ID: 31784984
[TBL] [Abstract][Full Text] [Related]
9. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
Kamran N; Chandran M; Lowenstein PR; Castro MG
Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
[TBL] [Abstract][Full Text] [Related]
10. Identification of Immune Cell Infiltration and Immune-Related Genes in the Tumor Microenvironment of Glioblastomas.
Huang S; Song Z; Zhang T; He X; Huang K; Zhang Q; Shen J; Pan J
Front Immunol; 2020; 11():585034. PubMed ID: 33193404
[TBL] [Abstract][Full Text] [Related]
11. Immune landscapes associated with different glioblastoma molecular subtypes.
Martinez-Lage M; Lynch TM; Bi Y; Cocito C; Way GP; Pal S; Haller J; Yan RE; Ziober A; Nguyen A; Kandpal M; O'Rourke DM; Greenfield JP; Greene CS; Davuluri RV; Dahmane N
Acta Neuropathol Commun; 2019 Nov; 7(1):203. PubMed ID: 31815646
[TBL] [Abstract][Full Text] [Related]
12. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
13. Brain Tumor Microenvironment and Host State: Implications for Immunotherapy.
Tomaszewski W; Sanchez-Perez L; Gajewski TF; Sampson JH
Clin Cancer Res; 2019 Jul; 25(14):4202-4210. PubMed ID: 30804019
[TBL] [Abstract][Full Text] [Related]
14. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment.
Jeanmougin M; Håvik AB; Cekaite L; Brandal P; Sveen A; Meling TR; Ågesen TH; Scheie D; Heim S; Lothe RA; Lind GE
Mol Oncol; 2020 May; 14(5):1016-1027. PubMed ID: 32171051
[TBL] [Abstract][Full Text] [Related]
15. Immune microenvironments differ in immune characteristics and outcome of glioblastoma multiforme.
Zhang B; Shen R; Cheng S; Feng L
Cancer Med; 2019 Jun; 8(6):2897-2907. PubMed ID: 31038851
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma: Relationship between Metabolism and Immunosuppressive Microenvironment.
Hernández A; Domènech M; Muñoz-Mármol AM; Carrato C; Balana C
Cells; 2021 Dec; 10(12):. PubMed ID: 34944036
[TBL] [Abstract][Full Text] [Related]
17. Glioblastoma-activated pericytes support tumor growth via immunosuppression.
Sena IFG; Paiva AE; Prazeres PHDM; Azevedo PO; Lousado L; Bhutia SK; Salmina AB; Mintz A; Birbrair A
Cancer Med; 2018 Apr; 7(4):1232-1239. PubMed ID: 29479841
[TBL] [Abstract][Full Text] [Related]
18. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
[TBL] [Abstract][Full Text] [Related]
19. The immune cell landscape of glioblastoma patients highlights a myeloid-enriched and immune suppressed microenvironment compared to metastatic brain tumors.
Musca B; Russo MG; Tushe A; Magri S; Battaggia G; Pinton L; Bonaudo C; Della Puppa A; Mandruzzato S
Front Immunol; 2023; 14():1236824. PubMed ID: 37936683
[TBL] [Abstract][Full Text] [Related]
20. Immune microenvironment of experimental rat C6 gliomas resembles human glioblastomas.
Gieryng A; Pszczolkowska D; Bocian K; Dabrowski M; Rajan WD; Kloss M; Mieczkowski J; Kaminska B
Sci Rep; 2017 Dec; 7(1):17556. PubMed ID: 29242629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
